Roberto Andreatini
Overview
Explore the profile of Roberto Andreatini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
96
Citations
1066
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lacerda G, Oliviera P, Vital M, Slomp Junior H, Galduroz J, Andreatini R
Acta Neuropsychiatr
. 2024 Oct;
36(4):189-194.
PMID: 39357069
There is a substantial use of Complementary and Alternative Medicine (CAM) among both the general population and psychiatric patients, with only a minority of these users disclosing this information to...
2.
Galduroz J, Campos-Junior M, Andreatini R
N Engl J Med
. 2024 Mar;
390(11):1056-1057.
PMID: 38478001
No abstract available.
3.
Santos A, Kuhl C, Higashijima A, Kanazawa L, de Souza S, Andreatini R
Fundam Clin Pharmacol
. 2024 Mar;
38(5):897-905.
PMID: 38472106
Background: Adenosinergic system has been implicated in the pathophysiology of bipolar disorder and drugs that affect adenosine neurotransmission have shown some efficacy as add-on therapy in manic patients. Objective: Thus,...
4.
Galduroz J, Zampronio A, Vital M, Sallet P, Zohar J, Andreatini R
Trends Psychiatry Psychother
. 2024 Jan;
PMID: 38240314
Neuroscience-Based Nomenclature (NbN) is a proposal to provide a nomenclature based on neuroscience and pharmacology instead of the old disease-based classification. NbN is based on the mechanism of action and...
5.
Saldanha T, Sanchez W, Palombo P, Cruz F, Galduroz J, Schwarting R, et al.
Behav Brain Res
. 2023 Dec;
461:114841.
PMID: 38159887
Cocaine use disorder (CUD) is a worldwide public health problem, associated with severe psychosocial and economic impacts. Currently, no FDA-approved treatment is available for CUD. However, an emerging body of...
6.
Cordeiro N, Pochapski J, Luna W, Baltazar G, Schwarting R, Andreatini R, et al.
Behav Brain Res
. 2023 Nov;
458:114759.
PMID: 37952685
Ultrasonic vocalizations (USV) are emitted by both young pups and adult rats to convey positive or negative emotional states. These USV manifestations are contingent on factors including developmental stage, situational...
7.
Andrade M, Souza L, Azevedo E, Bail E, Zanata S, Andreatini R, et al.
IBRO Neurosci Rep
. 2023 Mar;
14:264-272.
PMID: 36926592
Melatonin is a hormone secreted by the pineal gland, it can be associated with circadian rhythms, aging and neuroprotection. Melatonin levels are decreased in sporadic Alzheimer's disease (sAD) patients, which...
8.
Goncalves P, Pesquero B, Valentin D, Monteiro Pereira V, Andreatini R
Acta Neurobiol Exp (Wars)
. 2023 Feb;
82(4):511-520.
PMID: 36748974
Novel and effective treatments for mania are needed, and well‑validated animal models are important to reach this goal. The psychostimulant‑induced hyperactivity is the most frequently animal model of mania used....
9.
Ayub J, Luz Tosta C, Macedo B, Barreto T, Lopes L, Fracalossi M, et al.
Eur J Pharmacol
. 2022 Nov;
937:175382.
PMID: 36379258
Since a significant body of studies supports the involvement of glutamatergic neurotransmission in the neurobiology of obsessive-compulsive disorder (OCD). Ketamine, a glutamate N-methyl-D-aspartate (NMDA) receptor antagonist with rapid and sustained...
10.
Arjmand S, Landau A, Varastehmoradi B, Andreatini R, Joca S, Wegener G
Mol Psychiatry
. 2022 May;
27(8):3138-3149.
PMID: 35585261
Despite attaining significant advances toward better management of depressive disorders, we are still facing several setbacks. Developing rapid-acting antidepressants with sustained effects is an aspiration that requires thinking anew to...